BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM

1 day ago 7

MarketBeat

Fri, May 15, 2026 astatine 11:10 AM CDT 6 min read

4 Reasons Pfizer Could Be a Value Play You Can't Miss

BioNTech (NASDAQ:BNTX) utilized its virtual yearly wide gathering to outline a modulation twelvemonth marked by enactment changes, continued concern successful oncology, a planned stock repurchase programme and a restructuring of its manufacturing network.

Chairman of the Supervisory Board Helmut Jeggle said the 2025 fiscal twelvemonth was “a palmy one” for the company, citing advancement toward BioNTech’s extremity of becoming a multi-product institution by 2030. He said the institution ended 2025 with currency and marketable securities totaling EUR 17.2 billion, giving it “substantial resources” for its adjacent signifier of development.

Management Highlights Oncology Pipeline and BMS Partnership

→ Rocket Lab Just Hit a New All-Time High—Time to Buy oregon Let It Breathe?

Moderna Dips connected Q2 Earnings But Can It Rip connected a Short Squeeze?

Chief Executive Officer Professor Dr. Ugur Sahin, delivering what helium described arsenic his last yearly wide gathering code arsenic CEO, said BioNTech’s strategy remains focused connected 2 pillars: maintaining its COVID-19 vaccine concern with spouse Pfizer and utilizing proceeds to beforehand a diversified improvement pipeline, peculiarly successful oncology.

Sahin said BioNTech and Pfizer person delivered much than 5 cardinal COVID-19 vaccine doses worldwide since 2020. He added that BioNTech’s vaccine is distributed successful much than 180 countries and regions and has a marketplace stock of much than 50% successful cardinal markets.

→ Micron Investors Face a High-Stakes Moment After the Latest Rally

Novavax Plunges connected Earnings Miss: Falling Knife oregon Buying Opp?

In oncology, Sahin said BioNTech has much than 25 ongoing Phase 2 and Phase 3 studies, 17 objective programs and a objective grounds basal that includes much than 4,000 patients. He said the institution expects respective information updates from cardinal late-stage studies successful 2026.

Sahin highlighted pumitamig, BioNTech’s next-generation bispecific immunomodulator, arsenic the company’s “flagship program.” He said the campaigner has shown anti-tumor enactment crossed a wide scope of cancers based connected objective information to day and whitethorn person imaginable arsenic a operation spouse with different agents.

→ How Bad Could Tesla’s Cybertruck Recall Be for Shares?

BioNTech completed the acquisition of Biotheus successful aboriginal 2025, bringing pumitamig afloat into its pipeline, and successful June 2025 entered into a planetary 50/50 improvement and commercialization collaboration with Bristol Myers Squibb. Sahin said the statement includes a $1.5 cardinal upfront payment, $2 cardinal successful further unconditional payments and up to $7.6 cardinal successful milestone payments.

Read Entire Article